Pfizer Delays Generic Vyndamax Until 2031 – Great News for BridgeBio’s Attruby
Pfizer extends Vyndamax patent to 2031, delaying generics and giving BridgeBio more time to grow its rival heart drug without pressure.
Already have an account? Sign in.